David Steinberg

Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts.

Follica, Inc. develops therapies for hair follicle disorders. The firm provides an out-patient therapy coupled with an at-home system for the treatment of androgenetic alopecia (hair loss) and medical device development fields to develop and commercialize its product platform. The company was founded by Rox R. Anderson, George Cotsarelis, Vera Price, Daphne Zohar, David Steinberg, and Bernat Olle in 2006 and is headquartered in Boston, MA.

Enlight Biosciences LLC develops research tools for drug discovery and development. It offers patient-centric platforms that may impact all aspects of the connected health ecosystem from patient engagement and experience, to patient-focused research and development. The company was founded by Raju S. Kucherlapati, David Steinberg, Rakesh Kumar Jain, H. Robert Horbitz, and Sanjiv Sam Gambhir in July 2008 and is headquartered in Boston, MA.

Longwood Fund Management LLC (Longwood Fund) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Detwiler and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts.

Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA.

Entrega, Inc. develops oral drug delivery technologies. The firm’s platform enables novel applications in a variety of fields, such as disease management and tracking in the burgeoning mobile health arena. Its proprietary technology seeks to solve the oral delivery problem with an engineering solution that protects the payload and delivers biological molecules, drug substances and nanoparticles. The company was founded by Samir Mitragotri in 2010 and is headquartered in Boston, MA.

Knode, Inc. develops and delivers web-based life science solutions for accessing experts and their content. It offers solutions for project team formation, post-merger integration, collaborations, business development, and decision-making applications. The firm provides services to pharmaceutical companies, academic institutions and researchers. The company was founded in 2011 and is headquartered in Boston, MA.

Part of PureTech Health Plc, Commense, Inc. provides biotechnical research services. The company is based in Boston, MA. Edward J. Stewart has been the CEO of the company since 2018.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Be Biopharma, Inc. develops engineered B cells as a new category of cellular medicines. The company was founded by David Steinberg, Aleks Radovic-Moreno and Lea Hachigian and is headquartered in Cambridge, MA.

Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture.

Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.